Merck Serono Appoints Luciano Rossetti Global Head R&D
Merck Serono, the biopharmaceutical division of Merck, has appointed Dr Luciano Rossetti, Executive Vice President and Global Head of Research and Development, with effect from 21 July 2014.
In his most recent position, the Italian Rossetti (57) Senior Vice President of Late Stage Development was at Merck Sharp & Dohme (MSD). In this role he was responsible for the overall clinical development of Phase II to Phase V of all therapeutic disciplines away. Rossetti has the design and implementation of the development strategy for some potentially groundbreaking products such as anti-PD-1 significantly influenced at MSD. He has also restructured the field of clinical genetics to better interlink research and clinical development. Before Rossetti joined MSD in 2006, he worked for 18 years as an internationally recognized academic scientists.
"I am very pleased to welcome Luciano Rossetti at Merck," said Belén Garijo, President and CEO of the Merck Serono division. "With his wealth of experience, his successes in research and development, as well as his strong leadership profile, Luciano will contribute significantly to the development of our promising pipeline."
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.